NMRA

Neumora Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↓ 2/10
  • Momentum↑ 9/10
Neumora Therapeutics sales and earnings growth
NMRA Growth
Fair
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -22.50%
  • FCF Y/Y↓ -13.36%
Neumora Therapeutics gross and profit margin trends
NMRA Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -242.80%
Neumora Therapeutics net debt vs free cash flow
NMRA Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -315.1

Neumora Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗